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Abstract:
Background: Patent medicine vendors (PMVs) play an important role in the treatment of  malaria, especially in the rural 
areas. Nigeria recently changed her antimalarial treatment policy from chloroquine to artemisinin-based combination therapy 
(ACT).
Objectives: To determine the response of  PMVs to the new policy. 
Methods: A baseline study was conducted in two local government areas (LGAs) of  Lagos state Nigeria as the first phase in 
an intervention study aimed at improving the malarial treatment practices of  PMVs in rural Lagos. A mixed method design 
involving a questionnaire survey of  180 PMVs and four key informant interviews were used. An antimalarial drug (AMD) 
audit was also performed. 
Results: More than 80% of  respondents were aware of  the policy change in malaria treatment, but only 23.9%  sold an 
ACT for the last case of  malaria treated in an under five child. The main determining factor of  the particular AMD sold 
was PMV’s personal choice (70.6%). About half  (58.9%) of  the shops stocked ACTs, the newly recommended antimalarials. 
Conclusions: The high awareness of  the policy change did not translate to a commensurate increase in the sale of  the new 
drugs. Factors beyond the PMVs need to be addressed for a successful adoption of  the new policy. 
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Malaria remains a leading cause of  morbidity and mor-
tality in Nigeria as in other sub-Saharan Africa coun-
tries.1 Appropriate treatment of  uncomplicated malaria 
currently means the use of  artemisinin-based combina-
tion therapies (ACTs) as recommended by World Health 
Organization (WHO).2 Nigeria adopted ACTs as the 
drugs of  choice for the management of  uncomplicat-
ed malaria in 2004 following drug therapeutic effica-
cy trials which confirmed widespread resistance to the 
erstwhile drugs of  choice and demonstrated adequate 
response to selected ACTs.3 Artemether-Lumefantrine 
(AL) is the preferred ACT, while Artesunate-Amodi-
aquine (AA) is the alternate treatment.3 
Patent Medicine Vendors (PMVs) are important infor-
mal community-based providers of  health care, who 
by law are permitted to sell only patent (nonprescrip-
tion) medicines in their original prepackaged forms.4-6 
They operate in both urban and rural areas where they 
sell drugs by simply filling prescriptions, prescribe and 
then sell, instruct/advise clients on the use of  drugs 
sold, and refer clients to formal health facilities.7-9 Many 
countries, in their bids to ensure equitable access of  
the population to essential drugs, permit PMVs to sell 
over-the-counter (OTC) drugs, including antimalarials 
drugs (AMDs).10,11  Studies across Africa have shown 
that between 15% and 82% of  recent childhood illness-
es (most of  which are malaria) are managed by PMVs as 
the first provider of  care.5,6,12,13 This is supported by re-
cent studies in Nigeria14,15 including the Nigeria malaria 
indicator survey (2010)16 which reported that 57.4% of  
household members with fever used PMVs as the first 
treatment point. The burden of  malaria is known to be 
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heavier in the rural areas15,17 and it was estimated that 
58% of  malaria deaths occur in the poorest 20% of  
the world’s population, most of  who reside in the rural 
areas.18 
Studies have shown that despite change in antimalarial 
drug policy, both providers and consumers continued 
to use the erstwhile drugs for a long time for various 
reasons.19-22 This slow adoption is not without conse-
quences as the problems that necessitated the change 
remain.
PMVs’ shops belong to Level 1 in the three-level hierar-
chy of  disease management facilities in Nigeria. Others 
at this level are primary health care centres, dispensa-
ries and health posts.3 The PMVs are permitted to treat 
uncomplicated malaria with ACTs in the new policy.3 
This study aimed to assess the response of  the domi-
nant providers of  AMDs in the rural areas after about 
five years of  change in the antimalarial treatment policy. 
Methods 
Study setting
The study was conducted in Lagos State, which is one 
of  the 36 states of  the Federal Republic of  Nigeria. It is 
located in the southwestern zone and had an estimated 
population of  10,016,807 for 2009 as projected from 
the 2006 census.23 It is divided into 20 Local Govern-
ment Areas (LGAs); 16 are classified as urban and four 
as rural. The rural LGAs are Ikorodu, Epe, Ibeju-Lekki 
and Badagry.24 The study was carried out in Ikorodu and 
Ibeju-lekki LGAs.
There were two independent umbrella associations for 
PMVs in Lagos state: Lagos State Medicine Dealers’ As-
sociation (LSMDA) and National Association of  Patent 
and Proprietary Medicine Dealers (NAPPMED). The 
authors first established contact with LSMDA; it was 
much later while pre-testing the data collection instru-
ments that the parallel association was discovered. A de-
cision was made to limit the study to LSMDA to avoid 
the complexity of  involving the two bodies. LSMDA 
had a branch in each LGA and for ease of  administra-
tion; it subdivided its large LGAs into zones. 
Ikorodu had an estimated population of  580,236 for 
2009.23 The Ikorodu branch of  the Lagos State Medi-
cine Dealers Association (LSMDA) had 482 registered 
PMVs in its four zones and they were distributed thus: 
Ikorodu South (82), Ikorodu Central (75), Odogunyan 
(184) and Igbogbo (141). Ibeju-Lekki is another ru-
ral LGA in the state with an estimated population of  
129,467 for 2009.23 The Ibeju-Lekki branch of  LSMDA 
had 157 registered PMVs operating in the LGA. 
Study design
This report is from the pre-intervention phase of  an 
intervention study designed to improve the malarial 
treatment practices of  PMVs operating in rural Lagos. 
A mixed method design was used and it involved a 
questionnaire survey and key informant interviews. The 
study population comprised only LSMDA-registered 
PMVs operating in Ikorodu and in Ibeju-Lekki LGAs 
of  Lagos state. Where the shop owner was not the one 
actively involved in operating a selected shop, the per-
son in charge, either an apprentice or a sales attendant 
who usually sold drugs to clients was interviewed. 
Sample size estimation
The minimum sample size for the intervention study 
was estimated using the formula for comparison of  two 
proportions.25 A study conducted in Oyo state, which 
is in the same geopolitical zone with Lagos found that 
79.5% of  PMVs were aware of  the new policy.26 We ex-
pected our intervention to raise the awareness to at least 
95%. At alpha of  5% and power of  80%, and allowing 
for attrition and uncompleted interviews, 20% of  the 
size calculated was added and rounded up to 90. 
Sampling methodology
Ikorodu and Ibeju-Lekki LGAs were randomly selected 
(by balloting) out of  the four rural LGAs in the state. 
In Ikorodu, for methodological and logistical reasons, 
Odogunyan zone was purposively selected out of  the 
four zones in the LGA but the respondents were ran-
domly selected using a table of  random numbers. The 
table of  random numbers was also used to select the re-
spondents in Ibeju-Lekki. A list of  all registered PMVs 
in each study location constituted the sampling frame.
Data collection 
Data collection, which took place in July /September 
2009, was done using a pretested structured interview-
er-administered questionnaire, key informant interview 
guide and an observational checklist. One hundred and 
eighty PMVs (90 in each LGA) were interviewed and 
their shops were observed. One of  the authors and 
two trained research assistants administered the instru-
ments. The questionnaire elicited information on the 
socio-demographic characteristics of  the PMVs, their 
knowledge of  the new policy on malaria treatment and 
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their treatment practice. As an indicator of  the current 
treatment practice, the PMVs were asked to mention 
the AMD sold for the last case of  malaria treated in 
an under-five child. Drug audit was performed using a 
checklist. All the AMDs in stock for sale were identified. 
One of  each type of  the drugs was arbitrarily selected 
by the interviewer and checked for NAFDAC number 
and expiry date. The presence of  NAFDAC number is 
an indication that the product is duly registered. The 
chairperson and the secretary of  the association in each 
LGA were interviewed as key informants. The two were 
purposively selected as they were expected to have a 
good knowledge of  the subject matter and be able add 
depth to the interview. 
Data analysis
The Epi Info 2002 (Windows version 3.5.1) was used 
for data entry, cleaning, and analysis. The drugs with 
their different proprietary names were classified into 
the following broad generic groups: ACTs, artemisinin 
monotherapies (AMTs), and non-artemisinin thera-
pies (NATs). The ACTs were further classified into 
those containing artemether-lumefantrine (AL), ar-
tesunate-amodiaquine (AA) and others. Chi-square test 
(with Yates correction in 2 x 2 tables) and Fisher’s exact 
test were done to find association between categorical 
variables. Multiple logistic regression analysis was done 
to determine predictors of  ACT sale. A p-value < 0.05 
was considered statistically significant. The key inform-
ant interviews were tape-recorded, transcribed and or-
ganized under thematic headings. Content analysis28 was 
employed to identify responses and findings were pre-
sented under major themes. The main outcome meas-
ures were awareness of  the policy change, stocking and 
sale of  the recommended ACTs.
Ethical considerations 
Ethical approval for the study was obtained from the 
Research and Ethics Committee of  the Lagos Universi-
ty Teaching Hospital. Meetings were held with the exec-
utive bodies of  LSMDA at the state and LGA levels and 
they gave their consent for the study. Informed consent 
was also obtained from individual respondents and this 




Table 1 shows that most of  the respondents (148/82.2%) 
were shop owners and their ages ranged from 16 to 
67years. More than 90% had secondary education and 
31.7% had health training background, mainly auxilia-
ry nursing. Statistically significant differences exist be-
tween the two LGAs in some characteristics.
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Knowledge of  current malaria treatment policy 
Majority of  the PMVs (150/83.3%) reported being 
aware of  change in the malaria treatment policy but fur-
ther questions to establish their knowledge of  relevant 
components as it affects their practice showed only 10 
(5.6%) had good knowledge, 74 (41.1%) had fair knowl-
edge and 96 (53.3%) had poor knowledge of  the policy. 
Sale of  antimalarials and reasons for the sale
About a quarter (43/23.9%) of  respondents sold an 
ACT for the last case of  malaria treated in an under-five 
child, AMTs were sold by 37/20.6%, while NATs were 
the most frequently sold AMDs (100/55.6%) (Figure 
1). Figure 2 shows that 14/32.6% of  the ACTs sold 
were AL while 27/62.8% were AA combination. In 
127/70.6% of  AMD sales, the PMV made the choice 
(Figure 3). A further analysis of  the three determinants 
of  drug sale shows that NATs were the most frequent-
ly sold AMD by PMVs (67/52.8%) and also the most 
 
Figure 1: Antimalarial drug sold for the last under-five child treated for malaria 
 
Figure 2: Types of ACT sold for the last under-five child treated with an ACT 
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Figure 3: Determinant of antimalarial drug sold for the last under-five  
child treated for malaria 










Drug sale by PMV’s choice   
ACTs 12 (18.2) 23 (37.7) 35 (27.6) 7.24 0.027 
Artemisinin 
monotherapies 
17 (25.8) 8 (13.1) 25 (19.7)   
Non-artemisinin 
therapies 
37 (56.1) 30 (49.2) 67 (52.8)   
Total 66 (100.0) 61 (100.0) 127 (100.0)   
Drug sale by client’s specific demand   
ACTs 1(5.6) 2 (8.7) 3 (7.3)  0.648* 
Artemisinin 
monotherapies 
2 (11.1) 5 (21.7) 7 (17.1)   
Non-artemisinin 
therapies 
15 (83.3) 16 (69.6) 31 (75.6)   
Total 18 (100.0) 23 (100.0) 41 (100.0)   
Drug sale by prescription specification   
ACTs 2 (33.3) 3 (50.0) 5 (41.7)  0.567* 
Artemisinin 
monotherapy 
2 (33.3) 3 (50.0) 5 (41.7)   
Non-artemisinin 
therapy 
2 (33.3) 0 2 (16.7)   
Total 6 (100.0) 6 (100.0) 12 (100.0) 
 
  
*Fisher exact p-value 
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frequently demanded by clients (31/75.6%) (Table 2). 
Antimalarial drug audit
Table 3 shows the various types of  AMDs found in the 
drug shops. All the antimalarials examined had NAF-
DAC number and none had expired. ACTs were found 
in 58.9% of  the shops but a significant difference exists 
between the two groups (p<0.001). The NATs, main-
ly chloroquine (92.8%) and sulphadoxine-pyrimeth-
amine (87.8%) dominated the shops followed by AMTs 
(75.6%). 



























SP 81 (90.0) 77 (85.6) 158 (87.8) 0.47 0.495 
AMTs  66 (73.3) 70 (77.8) 136 (75.6) 0.27 0.603 
ACTs 39 (43.3) 67 (74.4) 106 (58.9) 16.73 <0.001 
Amodiaquine 17 (18.9) 10 (11.1)   27 (15.0) 1.57 0.210 
Pyrimethamine   3 (3.3) 10 (11.1)   13 (7.2) 2.98 0.084 
Halofantrine   2 (2.2) 10 (11.1)   12 (6.7) 4.38 0.036 
Quinine   4 (4.4)   7 (7.8)   11 (6.1) 0.39 0.534 
Others   0 (0.0)   3 (3.3)     3 (1.7)  0.246* 
*Fisher exact p-value 
Predictors of  ACT sale by PMVs
Multiple logistic regression analysis was done to iden-
tify predictors of  ACT sale among PMVs who made 
the choice of  AMD for their clients. Independent var-
iables in the model were respondent status, education, 
previous health-related training, previous CPD on ma-
laria, years of  practice, and awareness of  change in the 
treatment policy. None of  the factors was predictive of  
ACT sale.   
Key informant interview
Knowledge of  the current antimalarial treatment 
policy 
The four officials interviewed were aware of  change in 
the policy but none of  them knew the year the new 
guidelines came into effect. 
New drugs for treating malaria: All said ACTs are 
now the recommended drug for treating malaria in chil-
dren and adults. A chairperson explained, “Chloroquine 
is so abused and is no longer effective. Combination is 
needed now, AL or AA”. A secretary said, “we were told 
in Eko FM seminar that chloroquine and fansidar (an 
SP) are no longer active, that ACTs are the active ones.” 
Availability and affordability of  the new drugs: they 
all agreed that the drugs were available but the prices 
were high compared with CQ and SP. A chairperson 
said, “… the prices of  the new drugs are on the high 
side. For example fansidar is N130 – N150 ($0.93 - $1), 
Amatem (a brand of  AL) is N500 ($3.8), not in favour 
of  the poor masses.” Another chairperson added, “in-
itially so expensive, we don’t stock them. SFH (Society 
for Family Health) came in and subsidized just for chil-
dren. They supply only those who attended the semi-
nar they organized.” The drugs according to them were 
widely acceptable to buyers, only that many still could 
not afford them. Ikorodu secretary said, “they rely on 
what we tell them and they are convinced.” 
Discussion
This study examined the response of  PMVs in rural 
Lagos regarding malaria treatment about five years 
after change in policy from chloroquine to ACTs for 
the treatment of  uncomplicated malaria. The erstwhile 
first-line and second-line non-artemisinin therapies 
(NATs), i.e., chloroquine (CQ) and sulphadoxine-py-
rimethamine (SP) respectively, were still the most com-
monly sold AMDs for the treatment of  uncomplicated 
malaria in under-five children, a finding which is at var-
iance with the new policy recommendation. The sale 
mirrors the stock of  AMDs found on drug audit, which 
showed that CQ and SP still had dominion of  the mar-
ket. These findings are in consonance with other studies 
in Nigeria21,26,27  and elsewhere19,22 where, despite change 
in treatment policy, formerly used AMDs were still on 
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sale in drug shops even years after the change. The wide 
availability and sale of  CQ and SP implies that many 
cases of  uncomplicated malaria were still receiving in-
appropriate treatment with consequences including 
progression to severe illness, increased mortality and 
growing drug resistance.
Artemisinin monotherapies (AMTs) were the second 
most common group of  antimalarials in stock while 
ACTs were the third with a significant difference be-
tween the two LGAs. Regarding sale, overall, ACTs came 
a distant second to the NATs in the type of  AMDs sold 
but the pattern of  sale was different in the two LGAs. 
The type of  ACT sold also varies in the two LGAs and 
even though AL is the first line ACT, overall AA was the 
highest in sale volume. Both AA and AL are taken over 
three days but while AA is taken once daily, AL with a 
somewhat complex dosage regimen and more pills/syr-
up to swallow is taken twice daily. This may make AA 
more appealing to both the user (who would prefer a 
light drug burden) and the drug seller (who would have 
to explain how to use the drug). The differential ACT 
penetration and sale in the two LGAs shows that even 
in supposedly similar settings (both rural areas) diverse 
factors might be at play, including differences in drug 
supply chain and preferences of  clients. 
The continued presence of  AMTs in the shops is wor-
risome. Suspected resistance to artemisinins has been 
identified29 and there is growing concern that this may 
spread if  AMTs continue to be used. WHO has recom-
mended their withdrawal and replacement with ACTs 
but they are still widely on sale in many countries, most 
of  which are in Africa.29 The Pharmacists Council of  
Nigeria (PCN), which is the government regulatory 
agency that monitors the practice of  PMVs30 has not 
revised the approved list of  antimalarials PMVs are al-
lowed to sell31 to reflect the policy recommendation as 
at the time of  this study. The continued presence of  
the previously recommended drugs on the approved list 
may thereby create confusion and weaken adoption of  
the new policy. In addition, the availability of  non-ap-
proved AMDs in many shops is a pointer to weak reg-
ulation, enforcement and monitoring of  the practice of  
the PMVs by PCN. 
In this study, three factors determined malaria treat-
ment options. First, many clients simply approached 
the medicine sellers without any predetermined drug 
and the choice was left to the PMVs. Second, some 
buyers asked for a particular drug, and third a few came 
with a prescription. Just like a typical patient in a hospi-
tal leaves treatment decision for the clinician, more than 
70% of  the clients considered the PMV as the doctor 
whom they believed knew what was best for them. That 
only 27.6% of  these PMVs sold ACTs despite more 
than 80% of  them being aware of  the change suggests 
that factors beyond their knowledge played a significant 
role. None of  the hypothesized provider factors was 
predictive of  ACT sale by the PMVs. The officers of  
the PMVs’ association stated that many people could 
not afford the ACTs, though the drugs were acceptable 
to the communities. The PMVs seemed to respond to 
this by simply offering what they knew the people could 
afford i.e., CQ and SP. This was similar to the experi-
ence of  PMVs in the in-depth study in Enugu Nigeria.32 
All the respondents said they had heard of  artemisinin 
derivatives but none had it in their shops. One of  them 
captured their reason thus, “we cannot stock because 
of  the high cost. If  you do, no villager will buy it from 
you because they are very poor.”   
Majority of  the clients who bought AMD from the 
PMVs specifically demanded NATs. This suggests low 
level of  awareness of  the new drugs by the caregivers. 
Community based studies revealed poor awareness 
of  ACTs among households.15,21 This underscores the 
need for consumer education about the new treatment 
policy.
Limitations of  the study
Odogunyan zone in Ikorodu LGA was purposively se-
lected out of  the four zones and might theoretically not 
be representative of  the entire LGA. NAPPMED mem-
bers were not involved in the study. This limits gener-
alization of  the findings to all vendors operating in the 
rural areas of  Lagos state. Since information about the 
indicator of  drug sale was retrospectively collected, re-
call bias cannot be completely ruled out. 
Conclusions
Five years after change in antimalarial treatment poli-
cy, the high awareness among PMVs was yet to trans-
late to a commensurate increase in the sale of  the new 
drugs (ACTs). NATs and AMTs continued to dominate 
the market with dire consequences for malaria control. 
Factors beyond the PMVs like clients’ knowledge of  
the policy change, exorbitant prices of  the ACTs and 
continued availability of  older antimalarial drugs in the 
market need to be addressed in order to optimize the 
African Health Sciences Vol 15 Issue 2, June 2015
use of  ACTs. The authors recommend that the gov-
ernment should implement sustainable initiatives that 
will make ACTs more affordable to the people; gov-
ernment and other stakeholders in malaria control 
should enlighten the citizenry on the new drugs and 
discourage demand and use of  drugs that are no longer 
effective; the PCN should without further delay re-
vise the approved list of  antimalarial drugs PMVs are 
allowed to sell; and government should initiate effort 
to withdraw non-ACT antimalarials from the mar-
ket.                                                                                                                           
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